Sponsored Content
Serious setback for Intercell
The Vienna vaccine manufacturers has to terminate a research project unexpectedly at a late stage. Heavy losses are expected for this year.
Serious setback for Intercell / Picture: © Vindobona.org
Intercell has to terminate its program to develop a vaccine patch to stop travelling diarrhea. The clinical studies, contrary to expectations, promised too little protection against the travelling sickness. The costly project was already at a late stage of development. High write-off costs are the result: extraordinary expenses for € 167m are expected. Even if not the entire…
or Log In
Fast News Search